In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
1 Centre for Translational Neuroscience and Mental Health, School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia 2 Department of Physical Medicine and ...
Department of Physical Medicine and Rehabilitation, Harvard Medical School, Boston, Massachusetts, USA Correspondence to Professor Grant L Iverson, Department of Physical Medicine and Rehabilitation, ...
Hosted on MSN
‘Study my brain’: NFL shooter who killed four confirmed to have CTE; accused league of hiding brain injury risks
Shane Tamura, who drove from Las Vegas and opened fire at the NFL headquarters in New York, killing four people, was found to have CTE, the New York City Office of the Chief Medical Examiner confirmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback